Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Utah
OHSU Knight Cancer Institute
Bellicum Pharmaceuticals
OHSU Knight Cancer Institute
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Vifor Pharma
Second Affiliated Hospital, School of Medicine, Zhejiang University
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Masimo Corporation
Columbia University
University Hospital, Montpellier
German CLL Study Group
Mayo Clinic
Peking University
Northwestern University
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Stanford University
National Cancer Institute (NCI)
TME Pharma AG
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Vifor Pharma
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Ortho Biotech Products, L.P.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mayo Clinic
Sundsvall Hospital
National Institutes of Health Clinical Center (CC)